EUVIMEDObjevte EUVIMED
Open access · CC BY 4.0

From Antiretroviral to Antibacterial: Deep-Learning-Accelerated Repurposing and In Vitro Validation of Efavirenz Against Gram-Positive Bacteria

Ezzeldin Saleh, Omar A Soliman, Nancy Attia, Nouran Rafaat iD, Daniel Baecker iD, Mohamed Teleb, Abeer Ghazal, Ahmed Noby Amer iD

Molecules · 2025

DOI: 10.3390/molecules30142925 ↗

At a glance

Journal article in Molecules, 2025. Written by Ezzeldin Saleh and 7 co-authors. Institution: Microbiology Department, Medical Research Institute, Alexandria University, Alexandria 21521, Egypt. Major MEDLINE topics: Anti-Bacterial Agents, Drug Repositioning, Benzoxazines, Gram-Positive Bacteria. 33 references. The full text is freely available (open access, CC BY 4.0).

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

The repurposing potential of Efavirenz (EFV), a clinically established non-nucleoside reverse transcriptase inhibitor, was comprehensively evaluated for its in vitro antibacterial effect either alone or in combination with other antibacterial agents on several Gram-positive clinical strains showing different antibiotic resistance profiles. The binding potential assessed by an in silico study included Penicillin-binding proteins (PBPs) and WalK membrane kinase. Despite the relatively high minimum inhibitory concentration (MIC) limiting the use of EFV as a single antibacterial agent, it exhibits significant synergistic activity at sub-MIC levels when paired with various antibiotics against Enterococcus species and Staphylococcus aureus. EFV showed restored sensitivity of β-lactams against Methicillin-resistant S. aureus (MRSA). It increased the effectiveness of antibiotics tested against Methicillin-sensitive S. aureus (MSSA). It also helped to overcome the intrinsic resistance barrier for several antibiotics in Enterococcus spp. In silico binding studies aligned remarkably with experimental antimicrobial testing results and highlighted the potential of EFV to direct the engagement of PBPs with moderate to strong binding affinities (pKa 5.2–6.1). The dual-site PBP2 binding mechanism emerged as a novel inhibition strategy, potentially circumventing resistance mutations. Special attention should be paid to WalK binding predictions (pKa = 4.94), referring to the potential of EFV to interfere with essential regulatory pathways controlling cell wall metabolism and virulence factor expression. These findings, in general, suggest the possibility of EFV as a promising lead for the development of new antibacterial agents.

Subjects

MeSH terms (MEDLINE)

Anti-Bacterial AgentsDrug RepositioningBenzoxazinesGram-Positive BacteriaAnti-Retroviral AgentsAlkynesMicrobial Sensitivity TestsCyclopropanesMolecular Docking SimulationHumans

Author keywords

Efavirenzantibacterial activitydrug repurposingin silico binding study

Substances

AlkynesAnti-Bacterial AgentsBenzoxazinesCyclopropanesefavirenzAnti-Retroviral Agents

Authors and institutions

  • Microbiology Department, Medical Research Institute, Alexandria University, Alexandria 21521, Egypt.
  • Department of Clinical Pharmacy, Alexandria University Main Teaching Hospital, Alexandria 21526, Egypt.
  • Human Genetics Department, Medical Research Institute, Alexandria University, Alexandria 21521, Egypt.
  • Department of Infectious Diseases Surveillance, El Amereya Medical Area, Ministry of Health, Alexandria 53330, Egypt.
  • Department of Pharmaceutical and Medicinal Chemistry, Institute of Pharmacy, Freie Universität Berlin, Königin-Luise-Straße 2+4, 14195 Berlin, Germany.
  • Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Alexandria University, Alexandria 21521, Egypt.

ORCID profiles: Nouran Rafaat, Daniel Baecker, Ahmed Noby Amer

Cite

APA

Saleh, E., Soliman, O. A., Attia, N., Rafaat, N., Baecker, D., Teleb, M., Ghazal, A., & Amer, A. N. (2025). From Antiretroviral to Antibacterial: Deep-Learning-Accelerated Repurposing and In Vitro Validation of Efavirenz Against Gram-Positive Bacteria. Molecules. https://doi.org/10.3390/molecules30142925

Vancouver

Saleh E, Soliman OA, Attia N, Rafaat N, Baecker D, Teleb M, et al. From Antiretroviral to Antibacterial: Deep-Learning-Accelerated Repurposing and In Vitro Validation of Efavirenz Against Gram-Positive Bacteria. Molecules. 2025. doi:10.3390/molecules30142925

BibTeX
@article{Saleh2025,
  author = {Saleh, Ezzeldin and Soliman, Omar A and Attia, Nancy and Rafaat, Nouran and Baecker, Daniel and Teleb, Mohamed and Ghazal, Abeer and Amer, Ahmed Noby},
  title = {From Antiretroviral to Antibacterial: Deep-Learning-Accelerated Repurposing and In Vitro Validation of Efavirenz Against Gram-Positive Bacteria},
  journal = {Molecules},
  year = {2025},
  doi = {10.3390/molecules30142925}
}
Start for free →